IT - EN
News & Announcements

News & AnnouncementsBusiness & financial news

2020, October 1 - 18:07 RECORDATI: RECORDATI: MERGER BY ABSORPTION OF FIMEI S.P.A. AND ROSSINI INVESTIMENTI S.P.A. INTO RECORDATI S.P.A. APPROVED
2020, September 21 RECORDATI LICENSES AN INNOVATIVE EPINEPHRINE NASAL SPRAY IN DEVELOPMENT FOR ANAPHYLAXIS PREVENTION
2020, August 25 RECORDATI: U.S. FDA APPROVES CYSTADROPS® (Cysteamine Ophthalmic Solution) 0.37%, A NEW PRACTICAL TREATMENT OPTION FOR THE OCULAR MANIFESTATIONS OF CYSTINOSIS
2020, July 30 - 13:53 RECORDATI ANNOUNCES POSITIVE FIRST HALF 2020 RESULTS. REVENUES +2.3%, EBITDA +11.4%, ADJUSTED NET INCOME +16.8%
2020, July 17 ISTURISA® IS NOW AVAILABLE AS A MEDICAL TREATMENT FOR CUSHING'S SYNDROME IN GERMANY
2020, June 17 RECORDATI: ISTURISA® (OSILODROSTAT) PHASE III LINC-4 TRIAL MEETS ITS PRIMARY ENDPOINT IN CUSHING’S DISEASE
2020, June 2 Recordati Rare Diseases announces first European launch of Isturisa® (osilodrostat)
2020, May 27 RECORDATI RARE DISEASES INC. ANNOUNCES AVALABILITY OF ISTURISA® (OSILODROSTAT) IN THE UNITED STATES
2020, May 7 - 12:35 RECORDATI ANNOUNCES GROWTH IN THE FIRST QUARTER 2020. REVENUES +12.1%, EBITDA +20.1%
2020, April 29 - 12:11 RECORDATI SHAREHOLDERS APPROVE THE 2019 ACCOUNTS. DIVIDEND € 1.00 PER SHARE (+8.7% vs 2018)
2020, April 8 Recordati Rare Diseases is now the European Marketing Authorization holder of Isturisa® (osilodrostat) indicated for Adult patients with Endogenous Cushing’s Syndrome
2020, March 26 RECORDATI SUBMITS NEW DRUG APPLICATION FOR ISTURISA® IN JAPAN
2020, March 18 RECORDATI CONTRIBUTES TO SUPPORT HOSPITALS AND PATIENTS IN THE FACE OF THE EPIDEMIOLOGIC EMERGENCY DUE TO COVID-19
2020, March 18 - 14:11 BOARD APPROVES THE 2019 ACCOUNTS. SALES € 1,481.8 MILLION (+9.6%), EBITDA € 544.0 MILLION (+9.0%). 2019 DIVIDEND € 1.00 (+8.7%).
2020, March 12 - 19:59 RECORDATI: LAUNCH OF A NEW SHARE BUY-BACK PROGRAM TO SERVICE THE STOCK OPTION PLANS
2020, March 9 - 08:32 RECORDATI: ISTURISA® (OSILODROSTAT) APPROVED IN THE U.S.
2020, February 17 - 19:29 RECORDATI: LAUNCH OF A SHARE BUY-BACK PROGRAM TO SERVICE THE STOCK OPTION PLANS
2020, February 14 - 14:04 RECORDATI: PRELIMINARY 2019 RESULTS CONFIRM CONTINUED GROWTH OF SALES AND PROFITS. SALES +9.6%. EBITDA +9.0%.
2020, February 4 RECORDATI: CHANGE IN 2020 CORPORATE EVENTS’ CALENDAR
2020, January 15 - 12:01 RECORDATI: ISTURISA® (OSILODROSTAT) APPROVED
= price sensitive (as from 2015)